

HERBALIFE NUTRITION LTD.  
Form SC TO-I/A  
May 30, 2018

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**SCHEDULE TO**  
**TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1)**  
**OF THE SECURITIES EXCHANGE ACT OF 1934**  
**AMENDMENT NO. 4**

**HERBALIFE NUTRITION LTD.**

**(Name of Subject Company (Issuer))**

**Herbalife Nutrition Ltd.**

**(Name of Filing Persons (Offeror))**

**Common Shares, par value \$0.0005 per share**

**(Title of Class of Securities)**

**G4412G101**

**(CUSIP Number of Class of Securities)**

**Richard Werber**

**Chief Legal Officer**

**Herbalife Nutrition Ltd.**

**P.O. Box 309GT**

**Ugland House, South Church Street**

**Grand Cayman, Cayman Islands**

**(213) 745-0500**

**(Name, address, and telephone numbers of person authorized to receive notices and communications on behalf of filing persons)**

*Copies to:*

**Jonathan K. Layne**

**James J. Moloney**

**Gibson, Dunn & Crutcher LLP**

**2029 Century Park East**

**Los Angeles, CA 90067**

**(310) 552-8500**

**Calculation of Filing Fee**

**Transaction valuation\***

\$600,000,000

**Amount of filing fee\*\***

\$74,700\*\*\*

- \* Estimated for purposes of calculating the amount of the filing fee only, this amount is based on the purchase of common shares, par value \$0.0005 per share, of the Issuer for a maximum aggregate tender offer price of \$600,000,000.
- \*\* The amount of the filing fee, calculated in accordance with Rule 0-11(b) and Rule 1-11(d) of the Securities Exchange Act of 1934, as amended and Fee Rate Advisory #1 for Fiscal Year 2018 equals \$124.50 per \$1,000,000 of the aggregate value of the transaction.
- \*\*\* Amount Previously Paid: \$74,700.00 Form or Registration No.: Schedule TO-I Date Filed: April 18, 2018

Check the box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

Check the appropriate boxes below to designate any transactions to which the statement relates:

third-party tender offer subject to Rule 14d-1.  
issuer tender offer subject to Rule 13e-4.  
going-private transaction subject to Rule 13e-3.  
amendment to Schedule 13D under Rule 13d-2.

Check the following box if the filing is a final amendment reporting the results of the tender offer:

If applicable, check the appropriate box(es) below to designate the appropriate rule provision(s) relied upon:

Rule 13e-4(i) (Cross-Border Issuer Tender Offer)

Rule 14d-1(d) (Cross-Border Third-Party Tender Offer)

This Amendment No. 4 to the Tender Offer Statement on Schedule TO (the Amendment) filed by Herbalife Nutrition Ltd., a Cayman Islands exempted company incorporated with limited liability (the Company), amends and supplements the Schedule TO filed by the Company with the Securities and Exchange Commission (the SEC) on April 18, 2018, as amended by Amendment No. 1 to Schedule TO filed on April 27, 2018, Amendment No. 2 to Schedule TO filed on May 16, 2018, and Amendment No. 3 to Schedule TO filed on May 25, 2018 (collectively, with any amendments and supplements hereto, this Schedule TO). This Schedule TO relates to the offer by the Company to purchase common shares, par value \$0.0005 per share in the capital, of the Company (the common shares), for an aggregate cash purchase price of up to \$600 million at a price per share not greater than \$54.00 nor less than \$49.00 per share, net to the seller in cash, less any applicable tax withholding and without interest, upon the terms and subject to the conditions set forth in the Offer to Purchase, dated April 18, 2018 (the Offer to Purchase), and in the related Letter of Transmittal (the Letter of Transmittal which, together with the Offer to Purchase, as each may be amended or supplemented from time to time, collectively constitute the Offer), copies of which are annexed to and filed with this Schedule TO as Exhibits (a)(1)(A) and (a)(1)(B), respectively. The Offer expired at 5:00 P.M., New York City time, on Thursday, May 24, 2018.

The Schedule TO, and all the information set forth in the Offer to Purchase, to the extent incorporated by reference therein, is hereby amended and supplemented as set forth below. Every Item in the Schedule TO is automatically updated, to the extent such Item incorporates by reference any section of the Offer to Purchase that is amended and supplemented therein. All capitalized terms used but not otherwise defined in this Amendment have the meanings ascribed to such terms in the Offer to Purchase.

#### **Items 1 through 11.**

Items 1 through 11 of the Schedule TO are hereby amended and supplemented as follows:

Based on the final count by Computershare Trust Company, N.A., the Depository for the Offer (the Depository), a total of 49,705,756 common shares of the Company were properly tendered and not properly withdrawn at or below the Cash Purchase Price of \$52.50 per share.

Because the tender offer was oversubscribed, the Company purchased only a prorated portion of the common shares properly tendered by each tendering shareholder (other than odd lot holders whose shares were purchased on a priority basis) at the final per share Cash Purchase Price of \$52.50. Based on the final tender count, and taking into consideration the effect of odd lot priority on the proration factor, the final proration factor for the tender offer was 22.991123% of the shares properly tendered at or below the Cash Purchase Price of \$52.50 per share.

In accordance with the terms and conditions of the Offer and based on the final count by the Depository, the Company accepted for purchase 11,428,571 common shares of the Company at a Cash Purchase Price of \$52.50, for a total cash cost of approximately \$600 million, excluding fees and expenses relating to the Offer. These common shares represent approximately 6.5% of the Company's total outstanding common shares as of May 28, 2018. The Depository will promptly pay for the common shares accepted for purchase and promptly return all shares tendered and not accepted for purchase.

The Company expects to cancel all of the shares purchased pursuant to the Offer on June 4, 2018. After giving effect to the purchase and cancellation of the shares, the Company will have approximately 165.1 million common shares outstanding.

The full text of the press release issued by the Company announcing the final results of the Offer is attached hereto as Exhibit (a)(5)(E) and is incorporated herein by reference.

#### **Item 12. Exhibits.**

Item 12 of the Schedule TO is hereby amended and supplemented by adding the following Exhibits:

<b>Exhibit</b>	<b>Description</b>
(a)(5)(E)	Press release issued by the Company, dated May 30, 2018.

**EXHIBIT INDEX**

<b>Exhibit</b>	<b>Description</b>
(a)(1)(A) *	Offer to Purchase, dated April 18, 2018.
(a)(1)(B) *	Form of Letter of Transmittal (including IRS Form W-9).
(a)(1)(C) *	Form of Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.
(a)(1)(D) *	Form of Letter to Clients for Use by Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.
(a)(1)(E) *	Press release issued by the Company, dated April 18, 2018.
(a)(1)(F) *	Notice to Participants in the Company's Employee Stock Purchase Plan.
(a)(5)(A) *	Press release issued by the Company, dated April 24, 2018.
(a)(5)(B) *	Press release issued by the Company, dated April 27, 2018.
(a)(5)(C) *	Press release issued by the Company, dated May 16, 2018.
(a)(5)(D) *	Press release issued by the Company, dated May 25, 2018.
(a)(5)(E)	Press release issued by the Company, dated May 30, 2018.
(b)	Not applicable.
(d) #	Agreement by and among the Company and Carl C. Icahn and his controlled affiliates, dated August 21, 2017.
(g)	Not applicable.
(h)	Not applicable.

\* Previously filed

# Previously filed on August 21, 2017 as an Exhibit to the Company's Tender Offer Statement on Schedule TO and incorporated herein by reference.

**SIGNATURE**

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**HERBALIFE NUTRITION LTD.**

By: /s/ RICHARD WERBER  
Name: Richard Werber  
Title: *Chief Legal Officer*

Dated: May 30, 2018